The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.

doi:10.1016/j.xcrm.2025.101929

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.

Cell reports. Medicine - 18 Feb 2025

Oh Seung Yeon, Park Sewon, Lee Seoyoung, Lee Eun Ji, Kim Tae Ho, Choi Su-Jin, Park So Young, Kim Jae Hwan, Lim Sun Min, Lee Jii Bum, Cho Byoung Chul, Hong Min Hee, Yun Mi Ran

Abstract excerpt

Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) pose therapeutic challenge due to limited response to EGFR tyrosine kinase inhibitors (TKIs). This study presents preclinical evidence and mechanistic insights into the combination of lazertinib, a third-generation EGFR-TKI; and amivantamab, an EGFR-MET bispecific antibody, for treating NSCLC with uncommon EGFR...

Read the complete abstract on PubMed

Topics

Animals
Female
Humans
Male
Mice
Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Antineoplastic Combined Chemotherapy Protocols

Carcinoma, Non-Small-Cell Lung

Cell Line, Tumor

ErbB Receptors

Lung Neoplasms

Mutation

Protein Kinase Inhibitors

Quinolines

Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39874964
DOI: 10.1016/j.xcrm.2025.101929
PMCID: PMC11866483

Genes

EGFR
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.PMID 39874964Read ↗

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.Semantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.Semantic proximity Read ↗

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.Semantic proximity Read ↗

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.Semantic proximity Read ↗

EGFR-Mutant NSCLC: Spotlight on Amivantamab.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.